An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...

Research shows that eating a plant-based diet may offer protective benefits for heart health and prevention against certain ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...

For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its ...

New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.